These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 10837554)

  • 21. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans.
    Wilkinson GR
    J Pharmacokinet Biopharm; 1996 Oct; 24(5):475-90. PubMed ID: 9131486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity.
    Fayer JL; Zannikos PN; Stevens JC; Luo Y; Sidhu R; Kirkesseli S
    J Clin Pharmacol; 2001 Mar; 41(3):305-16. PubMed ID: 11269571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines.
    Madani S; Paine MF; Lewis L; Thummel KE; Shen DD
    Pharm Res; 1999 Aug; 16(8):1199-205. PubMed ID: 10468020
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?
    Doherty MM; Charman WN
    Clin Pharmacokinet; 2002; 41(4):235-53. PubMed ID: 11978143
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of intestinal first-pass drug metabolism.
    Yang J; Jamei M; Yeo KR; Tucker GT; Rostami-Hodjegan A
    Curr Drug Metab; 2007 Oct; 8(7):676-84. PubMed ID: 17979655
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo.
    Gorski JC; Huang SM; Pinto A; Hamman MA; Hilligoss JK; Zaheer NA; Desai M; Miller M; Hall SD
    Clin Pharmacol Ther; 2004 Jan; 75(1):89-100. PubMed ID: 14749695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differentiation of gut and hepatic first-pass effect of drugs: 1. Studies of verapamil in ported dogs.
    Lee YH; Perry BA; Lee HS; Kunta JR; Sutyak JP; Sinko PJ
    Pharm Res; 2001 Dec; 18(12):1721-8. PubMed ID: 11785692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature.
    Kato M; Chiba K; Hisaka A; Ishigami M; Kayama M; Mizuno N; Nagata Y; Takakuwa S; Tsukamoto Y; Ueda K; Kusuhara H; Ito K; Sugiyama Y
    Drug Metab Pharmacokinet; 2003; 18(6):365-72. PubMed ID: 15618757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of diet, aging and disease-states on presystemic elimination and oral drug bioavailability in humans.
    Wilkinson GR
    Adv Drug Deliv Rev; 1997 Sep; 27(2-3):129-159. PubMed ID: 10837555
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor.
    Lin JH; Chiba M; Balani SK; Chen IW; Kwei GY; Vastag KJ; Nishime JA
    Drug Metab Dispos; 1996 Oct; 24(10):1111-20. PubMed ID: 8894513
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytochrome P450-mediated metabolism in the human gut wall.
    Thelen K; Dressman JB
    J Pharm Pharmacol; 2009 May; 61(5):541-58. PubMed ID: 19405992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin.
    Fromm MF; Busse D; Kroemer HK; Eichelbaum M
    Hepatology; 1996 Oct; 24(4):796-801. PubMed ID: 8855178
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Can oral midazolam predict oral cyclosporine disposition?
    Paine MF; Davis CL; Shen DD; Marsh CL; Raisys VA; Thummel KE
    Eur J Pharm Sci; 2000 Nov; 12(1):51-62. PubMed ID: 11121733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate.
    Abuasal BS; Bolger MB; Walker DK; Kaddoumi A
    Mol Pharm; 2012 Mar; 9(3):492-504. PubMed ID: 22264132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.
    Barry M; Gibbons S; Back D; Mulcahy F
    Clin Pharmacokinet; 1997 Mar; 32(3):194-209. PubMed ID: 9084959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution.
    Emoto C; Murayama N; Rostami-Hodjegan A; Yamazaki H
    Curr Drug Metab; 2010 Oct; 11(8):678-85. PubMed ID: 20973757
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review: first-pass metabolism by the gastrointestinal mucosa.
    Back DJ; Rogers SM
    Aliment Pharmacol Ther; 1987 Oct; 1(5):339-57. PubMed ID: 2979678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dose-dependent intestinal and hepatic first-pass metabolism of midazolam, a cytochrome P450 3A substrate with differently modulated enzyme activity in rats.
    Higashikawa F; Murakami T; Kaneda T; Kato A; Takano M
    J Pharm Pharmacol; 1999 Jan; 51(1):67-72. PubMed ID: 10197420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fasting-Induced Changes in Hepatic P450 Mediated Drug Metabolism Are Largely Independent of the Constitutive Androstane Receptor CAR.
    de Vries EM; Lammers LA; Achterbergh R; Klümpen HJ; Mathot RA; Boelen A; Romijn JA
    PLoS One; 2016; 11(7):e0159552. PubMed ID: 27434302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates - an evaluation and case study using GastroPlus.
    Heikkinen AT; Baneyx G; Caruso A; Parrott N
    Eur J Pharm Sci; 2012 Sep; 47(2):375-86. PubMed ID: 22759901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.